Predictive factors for outcomes of half-dose photodynamic therapy combined with aflibercept for pachychoroid neovasculopathy
Authors:
- 8 March 2023
- journal article
- research article
- Published by Springer Nature in Graefe's Archive for Clinical and Experimental Ophthalmology
- Vol. 261 (8) , 2235-2243
Abstract
Purpose To assess the effects of half-dose photodynamic therapy (PDT) combined with an intravitreous aflibercept (IVA) injection for pachychoroid neovasculopathy (PNV) and its predictive factors. Methods Clinical information of 43 patients (43 eyes) with PNV obtained before and 6 months after treatment with half-dose PDT combined with IVA was retrospectively analyzed. Patients were categorized into the sufficient (25 eyes, 58.1%) or insufficient (18 eyes, 41.9%) group based on resolution or persistence/recurrence of subretinal fluid (SRF), respectively, and clinical data were compared. Macular neovascularization (MNV) change was studied in 30 cases with available pre- and post-treatment optical coherence tomography angiography images. Results The sufficient group included younger patients with better baseline best-corrected visual acuity (BCVA), more treatment-naïve eyes, and smaller MNV lesions at baseline than the insufficient group (all, P < 0.047). Complete SRF resolution was 81.8% in treatment-naïve eyes and only 33.3% in previously treated eyes. MNV expanded after half-dose PDT was combined with IVA regardless of the treatment outcome (P = 0.003). Conclusion Half-dose PDT combined with IVA was effective for PNV treatment, especially for younger patients with good baseline BCVA, treatment-naïve eyes, and small MNV sizes at baseline. MNV expanded after treatment regardless of the treatment outcomes.Keywords
Funding Information
- Japan Society for the Promotion of Science (KAKENHI JP 18K16953)
This publication has 27 references indexed in Scilit:
- Half-dose photodynamic therapy for chronic central serous chorioretinopathy evaluated by focal macular electroretinogramsJapanese Journal of Ophthalmology, 2017
- Intravitreal anti-vascular endothelial growth factor combined with half-fluence photodynamic therapy for choroidal neovascularization in chronic central serous chorioretinopathyEye, 2016
- Optical Coherence Tomography Angiography of Shallow Irregular Pigment Epithelial Detachments In Pachychoroid Spectrum DiseaseAmerican Journal of Ophthalmology, 2015
- One-Year Outcomes with Half-Dose Verteporfin Photodynamic Therapy for Chronic Central Serous ChorioretinopathyOphthalmology, 2015
- PACHYCHOROID NEOVASCULOPATHYRetina, 2015
- Photodynamic therapy for central serous chorioretinopathyEye, 2014
- TYPE 1 (SUB-RETINAL PIGMENT EPITHELIAL) NEOVASCULARIZATION IN CENTRAL SEROUS CHORIORETINOPATHY MASQUERADING AS NEOVASCULAR AGE-RELATED MACULAR DEGENERATIONRetina, 2012
- The protective role of Visudyne eyeglass® against VEGF synthesis after photodynamic therapy with verteporfinActa Ophthalmologica, 2009
- SAFETY ENHANCED PHOTODYNAMIC THERAPY FOR CHRONIC CENTRAL SEROUS CHORIORETINOPATHYRetina, 2008
- Safety enhanced photodynamic therapy with half dose verteporfin for chronic central serous chorioretinopathy: a short term pilot studyBritish Journal of Ophthalmology, 2006